Trials / Not Yet Recruiting
Not Yet RecruitingNCT07486869
Emapalumab MDA5 Rapidly Progressive Interstitial Lung Disease (RP-ILD) Study
Emapalumab for the Treatment of Anti-MDA5 Antibody Positive Rapidly Progressive Interstitial Lung Disease
- Status
- Not Yet Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 5 (estimated)
- Sponsor
- University of Miami · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a proof of concept study to determine if Emapalumab appears effective for the treatment of anti-MDA5 antibody positive rapidly progressive interstitial lung disease (MDA5 RP-ILD). Emapalumab is a medication that is currently used for a severe problem with the immune system, called macrophage activation syndrome, and this disease shares some similar features with MDA5 RP-ILD.
Conditions
- Dermatomyositis
- Dermatomyositis Sine Myositis
- Dermatomyositis With Myopathy
- Dermatomyositis With Respiratory Involvement
- Dermatomyositis With Organ Involvement
- Interstitial Lung Disease
- Interstitial Lung Disease Due to Connective Tissue Disease (Disorder)
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Emapalumab | Emapalumab administered intravenously according to the following dosing regimen: 6 mg/kg on Day 1, followed by 3 mg/kg every 3 days for 2 weeks, and then 3 mg/kg twice weekly for 2 weeks. |
Timeline
- Start date
- 2026-05-01
- Primary completion
- 2027-05-01
- Completion
- 2027-05-01
- First posted
- 2026-03-23
- Last updated
- 2026-04-09
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT07486869. Inclusion in this directory is not an endorsement.